02Aug
FDA Issues Cannabidiol Marketing Warning as Congressional Pressure for Action Continues
Following through with its promise to take enforcement actions against companies marketing cannabis-derived products that could put consumers at risk, the Food and Drug Administration (FDA) recently issued a warning letter to Curaleaf Inc., a...
By:
Wilson Sonsini Goodrich & Rosati
Related
In this five-part podcast series, I consider the use of monitors by state Attorneys General. I am jo...
Read More >
One of the most fundamental, but often overlooked, defenses in ERISA litigation is that the plaintif...
Read More >
Further to our bulletin published on 17 July 2019, the Private Security (General) Regulations 2019 h...
Read More >
Employers face a tight deadline of July 1 to comply with the civil provisions of Minnesota’s new Wa...
Read More >
The COVID-19 pandemic has caused cost overruns and project delays that construction owners and contr...
Read More >
In Kenney v. Helix TCS, Inc. No. 18-1105 (10th Cir. Sept. 20, 2019), the 10th Circuit Court of Appea...
Read More >